← Leaderboards
Anneke Catharina Hesseling
Stellenbosch University
$5,262,036
Attributed
$8,524,317
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2011–25$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,524,317 · 2
By mechanism
UM1$6,524,563 · 1
R01$1,999,754 · 1
Top collaborators
- Shaun Barnabas3 shared
- Mark Fredric Cotton2 shared
Most similar at Stellenbosch University
Same institution · by research overlap
- Shaun Barnabas$2,014,842
- Robin Mark Warren$521,206
- Mark Fredric Cotton$26,351,083
- Anthony Joseph Garcia-Prats$2,250,973
Others in their field
Top investigators on “Tuberculosis”
- Judith S. Currier · University Of California Los Angeles$301,722,065
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$297,204,160
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$267,912,117
- Lawrence Corey · Fred Hutchinson Cancer Center$255,939,398
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$200,192,298
- Sharon A Nachman · Johns Hopkins University$194,852,226
Research focus
TuberculosisTuberculosis DrugsPreventPharmaceutical PreparationsTreatment ResponseSouth AfricaDrug KineticsDrug InteractionsChildInterestRegimenSafetyAdultSamplingAnti-Retroviral AgentsDesignDiagnosticAntiretroviral TherapyAntitubercular AgentsAgedDrug Resistance In TuberculosisIncidencePreventionResistance
Grant awards (10)
Stellenbosch University Clinical Trials Unit$1,495,502
UM1 · FY2025 · AI · contact PI
Stellenbosch University Clinical Trials Unit$1,315,748
UM1 · FY2024 · AI · contact PI
Stellenbosch University Clinical Trials Unit$1,218,433
UM1 · FY2023 · AI · contact PI
Stellenbosch University Clinical Trials Unit$1,394,662
UM1 · FY2022 · AI · contact PI
Stellenbosch University Clinical Trials Unit$1,100,218
UM1 · FY2021 · AI · contact PI
PHARMACOKINETICS AND TOXICITY OF 2ND LINE ANTI-TB DRUGS IN HIV-INFECTED CHILDREN$392,469
R01 · FY2015 · HD · contact PI
PHARMACOKINETICS AND TOXICITY OF 2ND LINE ANTI-TB DRUGS IN HIV-INFECTED CHILDREN$391,328
R01 · FY2014 · HD · contact PI
PHARMACOKINETICS AND TOXICITY OF 2ND LINE ANTI-TB DRUGS IN HIV-INFECTED CHILDREN$390,498
R01 · FY2013 · HD · contact PI
PHARMACOKINETICS AND TOXICITY OF 2ND LINE ANTI-TB DRUGS IN HIV-INFECTED CHILDREN$403,759
R01 · FY2012 · HD · contact PI
PHARMACOKINETICS AND TOXICITY OF SECONDLINE ANTITUBERCULOSIS DRUGS IN HIV-INFECTE$421,700
R01 · FY2011 · HD · contact PI